For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 341,468 | 403,654.5* | 429,691 | 524,210 |
| General and administrative | 1,374,522 | 1,240,752.5* | 1,599,010 | 1,745,473 |
| Total operating expenses | 1,715,990 | 1,644,407 | 2,028,701 | 2,269,683 |
| Operating loss | -1,715,990 | -1,644,407* | -2,028,701 | -2,269,683 |
| Interest income | 35,008 | 36,472.5* | 35,911 | 23,404 |
| Net loss | -1,680,982 | -1,607,934.5 | -1,992,790 | -2,246,279 |
| Basic EPS | -0.62 | -0.957 | -1.23 | -1.89 |
| Diluted EPS | -0.62 | -0.957 | -1.23 | -1.89 |
| Basic Average Shares | 2,718,433 | 1,680,308 | 1,625,805 | 1,190,266 |
| Diluted Average Shares | 2,718,433 | 1,680,308 | 1,625,805 | 1,190,266 |
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)